Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Psoriasis finds that the continued uptake of Janssen's interleukin 12/23 inhibitor Stelara, which is expected to experience first-line biologic use ahead of the TNF-alpha inhibitors in the second half of the 2012-2022 forecast period, will drive sales growth. Stelara is forecast to achieve sales of $2.2 billion in 2022, accounting for 24 percent of total psoriasis sales. The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab) as well as Pfizer's Janus kinase inhibitor Xeljanz—will also drive sales through 2022. 

The findings also reveal that the TNF-alpha inhibitors, particularly AbbVie/Eisai's Humira, which has displaced Amgen/Stiefel/Pfizer/Takeda's Enbrel as the preferred first-line biologic, will continue to dominate as first-line biologic agents in the first half of our forecast. However, dermatologists will increasingly turn to Stelara for their biologic-naive patients, owing to the drug's favorable risk/benefit profile. T
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... ZURICH , May 28, 2015  Maetrics ( ... the life sciences sector, wrapped up a successful conference, ... the Medical Technology industry," today in Zurich ... ( http://www.maetrics.ch ) and its Switzerland ... regulation on the Medical Technology field to an exclusive ...
(Date:5/28/2015)... 28, 2015 The controversy surrounding the ... and myomectomies (procedures to remove uterine fibroids) continues, ... is investigating Johnson & Johnson,s Ethicon, Inc. unit, ... devices. According to the report published by The ... the FBI is trying to determine what the ...
(Date:5/28/2015)... 28, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... WebcastWhen: , Thursday, June 4 at 1:00 p.m. ET ... Live on the Internet.  Simply log onto our website ... the live event, a replay of the webcast will ... . ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... March 10, 2011, the company completed its previously ... About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ... manufactures and markets a broad range of pharmaceutical ...
... Inc. (Nasdaq: GNVC ) announced financial results for ... the year ended December 31, 2010, the Company reported a ... with a net loss of $18.4 million, or $0.19 per ... the year with $35.2 million in cash, cash equivalents, and ...
Cached Medicine Technology:GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 6GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 7GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 8
(Date:5/29/2015)... May 29, 2015 Dr. Rodger ... Chronic Fatigue Syndrome is now offering free weekly ... learn about natural ways to reduce symptoms associated ... poor sleep, and brain fog. , To ... and Beating Fibromyalgia call in teleconferences simply go ...
(Date:5/29/2015)... 2015 Javlin continues to fulfill its ... and a larger team, with the intention to better ... share in the U.S. and Canada. , Javlin Inc., ... significant growth in 2014 with its strongest earnings to ... integration platform, CloverETL. To accelerate further progress and ensure ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... has transformed the science of the little-known and ... it is co-funding the second FSHD Trial Preparedness ... 2015, at the University of Rochester Medical Center ... 50 stakeholders from around the world, including representatives ...
(Date:5/29/2015)... 2015 Health DataPalooza is a national ... discuss and foster the most effective and innovative ways ... Conference is hosted by the Health Data Consortium, which ... to promote and develop the use of open healthcare ... groups to narrow in on how to actually put ...
(Date:5/29/2015)... An organizational consultant and part-time college ... his memory and may be suffering from early dementia. ... professional life and in his uncertain relationship with his ... career working with corporate and government movers and shakers ... family members around him are being diagnosed with Alzheimer’s, ...
Breaking Medicine News(10 mins):Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 3Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2
... INC. (NYSE: RMD ),announced today that on Thursday, ... second quarter of fiscal year 2008, ended December 31,2007. ... p.m. Pacific,Time and will host a conference call to ... The conference call is scheduled to begin at 1:30 ...
... Board,Company (Nasdaq: ABCO ) announced today that it ... Williams, Chairman and Chief Executive,Officer, and Michael T. Kirshbaum, ... the quarter ended December 31, 2007. The,call will be ... Eastern Time.,The Company plans to release its third quarter ...
... QC, Jan. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... into a licensing and,distribution agreement with iNova Pharmaceuticals ... Australia., "Building on the launch of our ... continue to add strong distribution partners as we,prepare ...
... Jan. 24 Align,Technology, Inc. (Nasdaq: ALGN ... method of straightening teeth without wires or brackets, ... and launched a new, interactive web site to ... programs to meet the experience,level of almost every ...
... BRCA mutations would be more willing to test their own ... most U.S. medical groups are opposed, many people support genetic ... breast and/or ovarian cancer later in life, a new study ... Center in Philadelphia, and her colleagues interviewed 53 people ...
... HIV/AIDS Patients in Broward County and,Statewide, Community Open ... Testing, FT. LAUDERDALE, Fla., Jan. 24 AIDS,Healthcare ... ,Out of the,Closet, thrift store and ,AHF Pharmacy, location ... on Saturday, January 26th at 10:00 a.m. This,festive community ...
Cached Medicine News:Health News:RESMED to Webcast Second Quarter 2008 Earnings Conference Call 2Health News:The Advisory Board Company Schedules Third Quarter Investor Conference Call for February 5, 2008 2Health News:Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova 2Health News:Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova 3Health News:Align Technology Launches Aligntech Institute to Help Invisalign Providers Enhance Treatment Success and Practice Economics 2Health News:Align Technology Launches Aligntech Institute to Help Invisalign Providers Enhance Treatment Success and Practice Economics 3Health News:Next Generation of Parents More Likely to Back Genetic Testing 2Health News:AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors 'Out of the Closet' & 'AHF Pharmacy' 2Health News:AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors 'Out of the Closet' & 'AHF Pharmacy' 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: